|
Thank you for your role in supporting access to therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process. |
|
Federal Allocations
Week of November 7th:
mAbs Allocation Cycle
-
Evusheld (monthly): 2,436
Oral antivirals - Weekly (one week cycle)
-
Lagevrio (molnupiravir): 210
-
Paxlovid: 1,180
-
Renal Paxlovid: 105
|
|
Important Updates
OHA will be closed Friday, November 11th, 2022 in observance of Veterans Day. OHA will follow the usual cadence and asks that COVID-19 therapeutic orders be placed in HPOP by Wednesday, November 9th, 2022 by 11:59 PM.
Our October COVID-19 Therapeutics Newsletter is now available for therapeutics updates, events, community engagements and more!
Evusheld
-
Evusheld EUA fact sheet
-
NEW! Evusheld loses neutralization potency against BA.4.6 and potentially also against BF.7, BA.275.2 and BQ subvariants. See fact sheet for more information.
- Evusheld shelf life extensions
- Evusheld re-dosing
-
The AstraZeneca Call Center remains available should you have questions regarding the updated dosing guidance and/or the shelf-life extension for Evusheld. The AstraZeneca Call Center can be reached at 1-800-236-9933
-
Evusheld can now be directly ordered in small quantities for individual providers through this form: OrderEvusheld.com
-
Evusheld is now available at some Federally Registered Pharmacy Partners for patients with an Evusheld prescription
Bebtelovimab
-
Bebtelovimab EUA fact sheet
- NEW - November 4th, 2022- There is reduced activity against certain emerging Omicron subvariants of SARS-CoV-2, BQ.1 and BQ.1.1. However, Bebtelovimab remains authorized in all U.S. regions until further notice by the FDA. Prescribers should monitor CDC regional variant frequency data and refer to the health care provide fact sheet for details regarding specific variants and resistance against SARS-CoV-2 variants in your area.
-
Bebtelovimab shelf life extensions
-
Now commercially available for purchase
-
The Oregon Health Authority has limited supply of Bebtelovimab and will continue distribution of the product to Oregon providers until stock is depleted.
-
If you are a provider that serves primarily uninsured and underinsured populations, please utilize the Bebtelovimab Smartsheet Order Request Form to order from remaining OHA supply of Bebtelovimab
-
Providers who receive OHA supply must continue to report inventory and utilization in HPOP
Additional Resources
-
The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) sites and where to send prescriptions to be filled
-
Please check the locator periodically as sites continue to be added
-
The locator's accuracy relies on providers reporting inventory and utilization
-
If you are needing additional assistance with provider registration, ordering, or any other process related to therapeutics, please fill out the Office Hours Request Form to select office hour availability
-
For additional clinical guidance, please review the Multnomah County Clinician Alert and the University of Liverpool COVID-19 Drug Interaction tool
-
For additional guidance on the new ordering process, cadence, and reporting utilization, please review our Provider Operations Manual
-
For additional federal updates, shelf life extensions, and more, please visit the ASPR webpage
|
|
 Placing Requests
Product Case Size
Each product has a specific case size and is outlined below. When ordering, please consider the case size and order accordingly to ensure OHA can fulfill your requests properly.
- Evusheld - 12 courses
-
Bebtelovimab - 5 cases
-
Paxlovid - 20 courses
-
Renal Paxlovid - 5 courses
-
Lagevrio (molnupiravir) - 15 courses
Cadence
-
Monday - HHS notifies Oregon of our total therapeutics allotment.
NOTE: HHS informs Oregon of Evusheld’s total allotment monthly, every 4th Monday
-
Wednesday - Orders received by 11:59 p.m. will be allocated for the current week
-
Thursday/Friday - OHA staff will review the requests, determine allotments for each requesting site, and process via the Health Partner Ordering Portal (HPOP) by Friday.
NOTE: AmerisourceBergen anticipates shipping the products within 3-5 days of order submission.
Utilization reporting
Utilization reporting is a key component that HHS takes into consideration when determining each state’s allotment. Therefore, it is crucial that each site report their utilization twice a week on Mondays and Thursdays by 11:59pm, including for any product redistributed to other sites. Under-utilization in HPoP and under-reporting will affect Oregon’s future allocations.
Track your shipment
Once your packages are shipped by Amerisource Bergen, you can track them using Track My Shipment Tool.
For oral antivirals shipment tracking, please visit your HPOP account and reference "Therapeutic Shipping."
Thank you,
Oregon Health Authority
|
|
|
|
|
